Necrosis and Glioblastoma: A Friend or a Foe? A Review and a Hypothesis

OBJECTIVE Two main forms of cell death are encountered in biology: apoptosis (i.e., programmed cell death) and necrosis (i.e., accidental cell death). Because necrosis and apoptosis can lead to cell removal, one might intuit that they are both desirable in cancer treatment. However, in the setting of glioblastoma multiforme, a malignant brain tumor for which the presence of necrosis is an important diagnostic feature, clinical studies indicate that as the degree of necrosis advances, the patient’s prognosis worsens. Despite the apparent importance of this form of cell death, the mechanism of development of necrosis in glioblastomas remains unelucidated. The purpose of this article is to try to resolve this dilemma by hypothesizing the mechanism of necrosis formation in these tumors. METHODS On the basis of an extensive review of the literature, we present a hypothesis for the mechanism of necrosis formation in glioblastoma multiforme. RESULTS One of the many possible pathways leading to necrosis formation may involve increased tumor cell secretion of tumor necrosis factor. Procoagulation and antiapoptotic mechanisms resulting from certain pathways could prevent the completion of tumor necrosis factor-induced apoptosis and could promote necrosis as the final mode of cell death. Such a hypothesis would explain the inverse correlation that exists between tumor necrosis and the survival of patients with glioblastomas, because the hypoxia that results from procoagulation selects for tumor cells that are more aggressive and more resistant to apoptosis-inducing therapies. CONCLUSION A complete understanding of the series of events surrounding necrosis development in glioblastomas that is evidence-based is likely to provide targets for future therapies. On the basis of the potential mechanisms of development of necrosis described in this article, we postulate that effective therapies may have to be directed against the pathways that result in the formation of necrosis.

[1]  P. Nicotera,et al.  Intracellular Adenosine Triphosphate (ATP) Concentration: A Switch in the Decision Between Apoptosis and Necrosis , 1997, The Journal of experimental medicine.

[2]  A. Koong,et al.  Candidate genes for the hypoxic tumor phenotype. , 2000, Cancer research.

[3]  S. Targan,et al.  TNF-α antagonists for the treatment of Crohn’s disease , 2000 .

[4]  K. Hajjar,et al.  Interleukin 1 induces endothelial cell synthesis of plasminogen activator inhibitor , 1986, The Journal of experimental medicine.

[5]  M. Weber,et al.  Complexes of Ras.GTP with Raf-1 and mitogen-activated protein kinase kinase. , 1993, Science.

[6]  W. Fiers,et al.  More than one way to die: apoptosis, necrosis and reactive oxygen damage , 1999, Oncogene.

[7]  I. Verma,et al.  Induction of proto-oncogene JUN/AP-1 by serum and TPA , 1988, Nature.

[8]  A. Wyllie The biology of cell death in tumours. , 1985, Anticancer research.

[9]  P. Campbell,et al.  Immune protection and control of inflammatory tissue necrosis by gamma delta T cells. , 1994, Journal of immunology.

[10]  P. Nicotera,et al.  Energy supply and the shape of death in neurons and lymphoid cells , 1997, Cell Death and Differentiation.

[11]  J. Tschopp,et al.  Apoptosis induced by death receptors. , 2000, Pharmaceutica acta Helvetiae.

[12]  G. Semenza,et al.  Expression of hypoxia-inducible factor-1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. , 2001, Cancer research.

[13]  W. Fiers,et al.  Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin 1. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[14]  J. Vilček,et al.  Tumor necrosis factor: specific binding and internalization in sensitive and resistant cells. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[15]  M. Menger,et al.  Characterization of Angiogenesis and Microcirculation of High–Grade Glioma: An Intravital Multifluorescence Microscopic Approach in the Athymic Nude Mouse , 1998, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[16]  K. Hossmann,et al.  Blood Flow and Regulation of Blood Flow in Experimental Peritumoral Edema , 1981, Stroke.

[17]  N. Weidner,et al.  Correlation of intratumoral endothelial cell proliferation with microvessel density (tumor angiogenesis) and tumor cell proliferation in breast carcinoma. , 1994, The American journal of pathology.

[18]  R. Sawaya,et al.  Biological significance of tissue plasminogen activator content in brain tumors. , 1991, Journal of neurosurgery.

[19]  J. Miyazaki,et al.  Tumor necrosis factor alpha signaling pathway and apoptosis in pancreatic β cells , 1999 .

[20]  T. Gelehrter,et al.  Thrombin induction of plasminogen activator-inhibitor in cultured human endothelial cells. , 1986, The Journal of clinical investigation.

[21]  Z. Gokaslan,et al.  Inhibition of in vivo tumorigenicity and invasiveness of a human glioblastoma cell line transfected with antisense uPAR vectors , 1997, Clinical & Experimental Metastasis.

[22]  R. Medcalf,et al.  Plasminogen activator inhibitor 1 and 2 are tumor necrosis factor/cachectin-responsive genes , 1988, The Journal of experimental medicine.

[23]  G. Martin,et al.  Ras-independent oncogenic transformation by an EGF-receptor mutant. , 2000, Journal of cell science.

[24]  C. Vinson,et al.  Fibrin fragment induction of plasminogen activator inhibitor transcription is mediated by activator protein-1 through a highly conserved element. , 1999, Blood.

[25]  J. Folkman,et al.  Tumor angiogenesis: a quantitative method for histologic grading. , 1972, Journal of the National Cancer Institute.

[26]  P. Vaupel,et al.  Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. , 2001, Journal of the National Cancer Institute.

[27]  L. Rubin,et al.  Activated Phosphatidylinositol 3-Kinase and Akt Kinase Promote Survival of Superior Cervical Neurons , 1997, The Journal of cell biology.

[28]  R. Sawaya,et al.  Plasminogen activator activity and molecular weight patterns in human brain tumors. , 1988, Journal of neurosurgery.

[29]  S. R. Datta,et al.  Akt Phosphorylation of BAD Couples Survival Signals to the Cell-Intrinsic Death Machinery , 1997, Cell.

[30]  R. Sawaya,et al.  Postoperative venous thromboembolism and brain tumors: part III. Biochemical profile , 2004, Journal of Neuro-Oncology.

[31]  L. Gooding,et al.  Tumor necrosis factor can induce both apoptic and necrotic forms of cell lysis. , 1988, Journal of immunology.

[32]  A. Brunet,et al.  Growth factors induce nuclear translocation of MAP kinases (p42mapk and p44mapk) but not of their activator MAP kinase kinase (p45mapkk) in fibroblasts , 1993, The Journal of cell biology.

[33]  W. Fiers,et al.  Molecular mechanisms of tumor necrosis factor‐induced cytotoxicity , 1994, FEBS letters.

[34]  E. Keshet,et al.  Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis , 1992, Nature.

[35]  A. Harris,et al.  Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3'-kinase/Akt signaling pathway. , 2001, Cancer research.

[36]  G. Jayson,et al.  Heparin oligosaccharides: inhibitors of the biological activity of bFGF on Caco-2 cells. , 1997, British Journal of Cancer.

[37]  Raymond Sawaya,et al.  Prognostic significance of preoperative MRI scans in glioblastoma multiforme , 2004, Journal of Neuro-Oncology.

[38]  R. Rosenberg,et al.  Tumor necrosis factor suppresses transcription of the thrombomodulin gene in endothelial cells , 1988, Molecular and cellular biology.

[39]  B. Aggarwal,et al.  TNF-Induced Signaling in Apoptosis , 1999, Journal of Clinical Immunology.

[40]  J. S. Rao,et al.  Plasminogen activator inhibitor-1 in brain tumors: relation to malignancy and necrosis. , 1995, Neurosurgery.

[41]  L. Chess,et al.  Tumor necrosis factor/cachectin interacts with endothelial cell receptors to induce release of interleukin 1 , 1986, The Journal of experimental medicine.

[42]  Vijay R Baichwal,et al.  Apoptosis: Activate NF-κB or die? , 1997, Current Biology.

[43]  N. K. Sah,et al.  Oleandrin suppresses activation of nuclear transcription factor-kappaB, activator protein-1, and c-Jun NH2-terminal kinase. , 2000, Cancer research.

[44]  K. Kinzler,et al.  Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[45]  A. Wyllie,et al.  Apoptosis is inversely related to necrosis and determines net growth in tumors bearing constitutively expressed myc, ras, and HPV oncogenes. , 1994, The American journal of pathology.

[46]  D. Hallahan,et al.  Tumor necrosis factor α (TNF-α) gene therapy targeted by ionizing radiation selectively damages tumor vasculature , 1996 .

[47]  A. Ullrich,et al.  Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis. , 1993, Cancer research.

[48]  R. Cotran,et al.  Interleukin 1 (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells , 1984, The Journal of experimental medicine.

[49]  Eric C. Holland,et al.  Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice , 2000, Nature Genetics.

[50]  S. Ghosh,et al.  Inhibition of NF-kappa B by sodium salicylate and aspirin. , 1994, Science.

[51]  P. Tsichlis,et al.  Transduction of interleukin-2 antiapoptotic and proliferative signals via Akt protein kinase. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[52]  Nelson Lau,et al.  Signal transduction pathways and their relevance in human astrocytomas , 1997, Journal of Neuro-Oncology.

[53]  N. Sato,et al.  Effects of tumor necrosis factor (TNF) on transplanted tumors induced by methylcholanthrene in mice , 1986, Virchows Archiv. B, Cell pathology including molecular pathology.

[54]  L. Platanias,et al.  Activation of the Akt/FKHRL1 pathway mediates the antiapoptotic effects of erythropoietin in primary human erythroid progenitors. , 2000, Biochemical and biophysical research communications.

[55]  H. Allgayer,et al.  A region between -141 and -61 bp containing a proximal AP-1 is essential for constitutive expression of urokinase-type plasminogen activator receptor. , 1999, European journal of biochemistry.

[56]  C. Der,et al.  Oncogenic Ha-Ras-induced Signaling Activates NF-κB Transcriptional Activity, Which Is Required for Cellular Transformation* , 1997, The Journal of Biological Chemistry.

[57]  J F Kerr,et al.  Shrinkage necrosis: A distinct mode of cellular death , 1971, The Journal of pathology.

[58]  R K Jain,et al.  Determinants of tumor blood flow: a review. , 1988, Cancer research.

[59]  K. Hamilton,et al.  Tumour necrosis factor-α blockade: a new era for effective management of rheumatoid arthritis , 2000, Expert opinion on pharmacotherapy.

[60]  A. Wyllie Cell death: a new classification separating apoptosis from necrosis , 1981 .

[61]  Z L Gokaslan,et al.  A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. , 2001, Journal of neurosurgery.

[62]  P. Black,et al.  Expression of platelet derived growth factor and platelet derived growth factor receptor mRNA in a glioblastoma from a patient with Li-Fraumeni syndrome. , 1995, Journal of neurology, neurosurgery, and psychiatry.

[63]  D. Vaux Toward an understanding of the molecular mechanisms of physiological cell death. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[64]  A. Krüger,et al.  Hydroxamate-type matrix metalloproteinase inhibitor batimastat promotes liver metastasis. , 2001, Cancer research.

[65]  C. Marshall,et al.  Specificity of receptor tyrosine kinase signaling: Transient versus sustained extracellular signal-regulated kinase activation , 1995, Cell.

[66]  T. Oostendorp,et al.  Vascularity and perfusion of human gliomas xenografted in the athymic nude mouse. , 1995, British Journal of Cancer.

[67]  D. Groothuis,et al.  Regional blood flow in ethylnitrosourea‐induced brain tumors , 1983, Annals of neurology.

[68]  M. Menger,et al.  Vascular Microenvironment in Gliomas , 2000, Journal of Neuro-Oncology.

[69]  A. Giaccia,et al.  Tumor hypoxia, the physiological link between Trousseau's syndrome (carcinoma-induced coagulopathy) and metastasis. , 2001, Cancer research.

[70]  E Farber,et al.  Programmed cell death: necrosis versus apoptosis. , 1994, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[71]  D. Stern,et al.  Modulation of endothelial cell hemostatic properties by tumor necrosis factor , 1986, The Journal of experimental medicine.

[72]  Georg Breier,et al.  Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo , 1992, Nature.

[73]  D. Bigner,et al.  Regional measurements of blood flow in experimental RG-2 rat gliomas. , 1983, Cancer research.

[74]  A. Aguzzi,et al.  Angiogenesis in Transgenic Models of Multistep Carcinogenesis , 2004, Journal of Neuro-Oncology.

[75]  B. Aggarwal,et al.  Triple helix-forming oligodeoxyribonucleotides targeted to the human tumor necrosis factor (TNF) gene inhibit TNF production and block the TNF-dependent growth of human glioblastoma tumor cells. , 1996, Cancer research.

[76]  David E. Housman,et al.  Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours , 1996, Nature.